SCHEMBL23182732

SCHEMBL23182732

C=C(CCNC(=O)COc1ccc(Cl)cc1)NC(=O)Cc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.52
▸ KMT2A Q03164 5/20 0.49
▸ MEN1 O00255 4/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ BCHE P06276 1/20 0.47
▸ ACHE P22303 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ ALOX12 P18054 1/20 0.47
▸ LTA4H P09960 1/20 0.47
▸ EPHX2 P34913 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ HDAC1 Q13547 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23182908 0.91 KDM4E (0.54) HTTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL23383779 0.86 MEN1 (0.50) HTTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL23182750 0.86 SMN1; SMN2 (0.55) HTTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL23182881 0.85 HDAC1 (0.61) HTTKMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL23384162 0.85 KMT2A (0.49) HTTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL23384172 0.85 MEN1 (0.49) HTTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL23383744 0.85 HTT (0.57) HTTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL23182495 0.85 TDP1 (0.54) HTTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL23383781 0.84 MEN1 (0.48) HTTKMT2AMEN1CYP1A2CYP2C9
SCHEMBL23383660 0.84 KDM4E (0.51) HTTKMT2AMEN1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210093619-A1 Chemical Compounds as ATF-4 Pathway Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210093619-A1 Chemical Compounds as ATF-4 Pathway Inhibitors ATF4, ATF1, XBP1 HTT 3117/4885KMT2A 2770/4885MEN1 4697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback